Patrick Y Wen
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
van den Bent M, Zhang H, Balbin O, Vicente S, Cheng Y, Kirsilae T, Zhao S, Tiedt R, Rodón J, Tabatabai G, Jörger M, Lassman A, Wen P, Yung W, Sepulveda J, De Vos F, Azaro A, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019
27.11.2019A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
27.11.2019J Neurooncol 2019
van den Bent Martin, Zhang Hefei, Balbin O Alejandro, Vicente Sergio, Cheng Yi, Kirsilae Tiina, Zhao Sylvia, Tiedt Ralph, Rodón Jordi, Tabatabai Ghazaleh, Jörger Markus, Lassman Andrew B, Wen Patrick Y, Yung W K Alfred, Sepulveda Juan, De Vos Filip, Azaro Analia, Wick Wolfgang
Angiogenesis inhibitors in tackling recurrent glioblastoma
Hundsberger T, Reardon D, Wen P. Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther 2017
24.04.2017Angiogenesis inhibitors in tackling recurrent glioblastoma
24.04.2017Expert Rev Anticancer Ther 2017
Hundsberger Thomas, Reardon David A, Wen Patrick Y